§ 01 Overview
Overview
Small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT) that increases intracellular NAD+ and SAM and may reduce adiposity.
Strong mouse model data. No substantial human clinical trials published to date.
§ 02 Mechanism
Mechanism of action
5-Amino-1MQ inhibits NNMT, an enzyme overexpressed in white adipose tissue of obese subjects. Inhibition preserves methyl donors and NAD+, shifting adipocytes toward a leaner, more thermogenic phenotype in preclinical models.
- 01Preclinical reduction in adiposity
- 02Increased NAD+ and SAM availability
- 03Improved metabolic markers in animal studies
§ 03 Dosing
Dosing protocol
Standard Protocol
- Dose Range
- 50 – 150 mg daily (anecdotal)
- Starting Dose
- 50 mg daily
- Route
- Oral
- Timing
- AM
- Frequency
- Daily
- Cycle
- 8 weeks on, 4 off
§ 04 Evidence
Evidence & research
Strong mouse model data. No substantial human clinical trials published to date.
FDA Status
Not FDA-approved. Sold as research chemical.
§ 06 News
In the news
4 articles from the last 12 months · updates hourly
Volta Peptides Wins Research Peptide Supplier of the Year 2026 Award from Peptide Atlas - USA Today
Volta Peptides Wins Research Peptide Supplier of the Year 2026 Award from Peptide Atlas USA Today
OMNI Peptides Launches U.S. Research Peptide Website Built Around Verified Purity and Batch-Level Transparency - TMX Newsfile
OMNI Peptides Launches U.S. Research Peptide Website Built Around Verified Purity and Batch-Level Transparency TMX Newsfile
I bought peptides with crypto. How my purchase helped fuel a $100 million gray-market, ‘looksmaxxing’ economy - Fortune
I bought peptides with crypto. How my purchase helped fuel a $100 million gray-market, ‘looksmaxxing’ economy Fortune
FDA Sends 30 Warning Letters To Continue Clampdown on Compounded GLP-1s - BioSpace
FDA Sends 30 Warning Letters To Continue Clampdown on Compounded GLP-1s BioSpace
§ 07 Sourcing
Sourcing & supply
Regulatory status
Research-only, no commercial channel
No commercial channel exists. Available only as a research reagent from RUO suppliers. Use in humans is not established.
Research-use-only · 1
Limitless Life Nootropics
'Only BBB-accredited peptide company' (since 2020). Claims three-lab third-party testing. Broad catalog.
Listings are informational, not endorsement. Verify credentials and flags against FDA and PCAB databases before purchasing. Full directory & how to verify →
§ 09 Safety
Safety & side effects
Side effects
- 01Insufficient human safety data
- 02Possible methylation effects
Contraindications
None specified.
§ 10 Questions
5-Amino-1MQ FAQ
- What is 5-Amino-1MQ?
- Small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT) that increases intracellular NAD+ and SAM and may reduce adiposity. 5-Amino-1MQ inhibits NNMT, an enzyme overexpressed in white adipose tissue of obese subjects. Inhibition preserves methyl donors and NAD+, shifting adipocytes toward a leaner, more thermogenic phenotype in preclinical models.
- What is 5-Amino-1MQ used for?
- Reported uses include preclinical reduction in adiposity, increased nad+ and sam availability, and improved metabolic markers in animal studies. Evidence strength is rated Preclinical — see the evidence section for detail.
- How is 5-Amino-1MQ dosed?
- Commonly referenced dosing is 50 – 150 mg daily (anecdotal), administered Oral. This is educational reference only; consult a licensed clinician before use.
- What are the side effects of 5-Amino-1MQ?
- Commonly reported side effects include insufficient human safety data and possible methylation effects. This list is not exhaustive.
- Is 5-Amino-1MQ legal?
- No commercial channel exists. Available only as a research reagent from RUO suppliers. Use in humans is not established. FDA status: Not FDA-approved. Sold as research chemical..